A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Report

PURPOSE: To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors. EXPERIMENTAL DESIGN: Cixutumumab and temsirolimus were administered in...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Cancer Res
Main Authors: Fouladi, Maryam, Perentesis, John P., Wagner, Lars M., Vinks, Alexander A., Reid, Joel M., Ahern, Charlotte, Thomas, George, Mercer, Carol A., Krueger, Darcy A., Houghton, Peter J., Doyle, L. Austin, Chen, Helen, Weigel, Brenda, Blaney, Susan M.
格式: Artigo
語言:Inglês
出版: 2014
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4454739/
https://ncbi.nlm.nih.gov/pubmed/25467181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0595
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍